Faron

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. Its lead program is bexmarilimab, its investigative precision immunotherapy in Phase I/II development as a novel macrophage checkpoint immunotherapy for patients with hematological malignancies. Bexmarilimab is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Faron is based in Turku, Finland and Boston, Massachusetts. Faron is listed on AIM under the ticker FARN and Nasdaq First North Growth Market (Nasdaq First North) under ticker FARON

Drug discovery,drug development,pharmaceuticals,novel treatments for medical conditions with significant unmet needs,ards,acute respiratory distress syndrome,cancer immunotherapy,and biopharmaceutical

Faron operates in the Pharmaceutical manufacturing industry.

Faron's HQ phone number is 212-362-1200

Faron's revenue is 11m - 100m

Faron has 11 - 50 employees.